Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 12/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30936872 | 1.00 | CYP19A1 (0.37) | CYP19A1ALDH1A1CYP3A4KMT2ALMNA | |
| SCHEMBL29686091 | 0.89 | ALDH1A1 (0.44) | CYP19A1ALDH1A1CYP3A4KMT2ALMNA | |
| SCHEMBL23933005 | 0.89 | ALDH1A1 (0.44) | CYP19A1ALDH1A1CYP3A4KMT2ALMNA | |
| SCHEMBL29686620 | 0.79 | KMT2A (0.47) | CYP19A1ALDH1A1CYP3A4KMT2ALMNA | |
| SCHEMBL24498465 | 0.79 | KMT2A (0.47) | CYP19A1ALDH1A1CYP3A4KMT2ALMNA | |
| SCHEMBL24498481 | 0.79 | CYP19A1 (0.49) | CYP19A1ALDH1A1KMT2ALMNA | |
| SCHEMBL30937011 | 0.77 | POLB (0.46) | CYP19A1ALDH1A1 | |
| SCHEMBL26906921 | 0.76 | ALDH1A1 (0.44) | CYP19A1ALDH1A1CYP3A4KMT2ALMNA | |
| SCHEMBL20073375 | 0.74 | TDP1 (0.43) | CYP19A1ALDH1A1CYP3A4KMT2ALMNA | |
| SCHEMBL29686578 | 0.74 | TDP1 (0.43) | CYP19A1ALDH1A1CYP3A4KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024072178-A1 | COMPOUND FOR TARGETED PROTEIN DEGRADATION, AND USE THEREOF | (주)사이러스테라퓨틱스 | 2024-04-04 | — | — | WO | disclosed |